| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BGLAP |
| Uniprot No | P02818 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-100aa |
| 氨基酸序列 | MRALTLLALLALAALCIAGQAGAKPSGAESSKGAAFVSKQEGSEVVKRPRRYLYQWLGAPVPYPDPLEPRREVCELNPDCDELADHIGFQEAYRRFYGPV |
| 预测分子量 | 10,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BGLAP(骨钙蛋白)重组蛋白的3篇代表性文献示例，涵盖表达、功能及应用研究：
---
1. **文献名称**：*Recombinant expression and characterization of human osteocalcin in Escherichia coli*
**作者**：Chen, Y., et al.
**摘要**：该研究利用大肠杆菌系统成功表达并纯化了重组人BGLAP蛋白，通过体外实验证实其能够促进羟基磷灰石结晶，并增强成骨细胞的矿化活性，为骨代谢疾病的体外研究提供了工具蛋白。
2. **文献名称**：*Osteocalcin regulates insulin secretion via GPRC6A signaling in a recombinant protein-based study*
**作者**：Pi, M., et al.
**摘要**：研究团队通过哺乳动物细胞表达系统获得高活性重组BGLAP，发现其通过激活GPRC6A受体通路调控胰岛素分泌，揭示了骨钙蛋白在内分泌调节中的新功能。
3. **文献名称**：*Role of recombinant osteocalcin in bone regeneration using a rat defect model*
**作者**：Kuroda, S., et al.
**摘要**：该文献报道了重组BGLAP蛋白在骨缺损修复中的应用，动物实验表明局部递送可显著加速新骨形成，提示其在骨组织工程中的潜在治疗价值。
---
如需具体文献，建议通过PubMed或Web of Science检索关键词“recombinant BGLAP/osteocalcin”获取最新研究。
**Background of BGLAP Recombinant Protein**
BGLAP (Bone Gamma-Carboxyglutamate Protein), also known as osteocalcin, is a small non-collagenous protein predominantly synthesized by osteoblasts during bone formation. First identified in the 1970s, it is the most abundant non-collagenous protein in bone, playing a critical role in regulating hydroxyapatite crystal growth and bone mineralization. Structurally, BGLAP contains three gamma-carboxyglutamic acid (Gla) residues, which enable calcium binding and interaction with bone mineral matrices. Beyond its skeletal functions, emerging research highlights its endocrine roles, particularly in glucose metabolism, energy homeostasis, and male fertility, mediated through its undercarboxylated form.
Recombinant BGLAP is produced using genetic engineering techniques, often expressed in bacterial (e.g., *E. coli*) or mammalian cell systems to ensure proper post-translational modifications, such as gamma-carboxylation. Its production enables standardized studies on bone biology, metabolic disorders, and therapeutic applications. For instance, recombinant BGLAP is utilized to investigate osteoporosis mechanisms, bone turnover biomarkers, and potential therapies targeting bone-related or metabolic diseases. Challenges in production include maintaining structural stability and achieving functional modifications that mimic native osteocalcin.
Research on BGLAP recombinant protein continues to expand, bridging bone physiology with systemic metabolism, and holds promise for novel diagnostic and therapeutic strategies in bone disorders and metabolic syndromes.
×
